Researchers identify DNA marker that could predict treatment response in myelodysplastic syndromes
DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine. That's the key finding of a new multicenter study involving researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
